Essure side effects can occur during or after the procedure. Some Essure problems are mild and last only a few days. Others such as organ perforation and device migration may require a hysterectomy to treat. The U.S. Food and Drug Administration has received thousands of Essure birth-control side-effect reports. In July 2018, Bayer announced Essure sales in the U.S would end within six months.
If you had Essure Permanent Birth Control System inserted and you're suffering from complications, you may be entitled to compensation.
Essure is the only nonsurgical permanent birth control option approved for women ages 21 to 45. The device may lead to serious side effects.
The U.S. Food and Drug Administration has received thousands of Essure side effect reports since the device hit the market in 2002. Reported side effects range from mild pelvic pain to death.
The FDA placed a black box warning on Essure in November 2016. It warns that some side effects are serious and may require surgery.
Severe side effects led some women to file Essure lawsuits against the device’s maker, Bayer.
In April 2018, the FDA limited the sale of Essure to health care providers who use a checklist to warn patients of risks. In July 2018, Bayer announced the product would no longer be sold in the U.S. by Dec. 31, 2018.
Some Essure side effects are mild. They may go away in a few days.
But some symptoms may mean there’s a more serious Essure complication. They require immediate attention.
Some examples of serious symptoms include chronic pelvic pain, heavy bleeding in between periods and bowel problems.
Women should see their doctor about any serious symptoms that persist.
Women may experience Essure problems during Essure insertion. They may also experience side effects immediately after the procedure.
The Essure procedure is nonsurgical. Doctors insert metal coils into the fallopian tubes through the vagina.
During the procedure, women may experience short-term side effects or complications. Some are mild and go away on their own. Others may need surgery to treat.
The Essure procedure is an outpatient procedure. Most women can leave the office in less than an hour. Some may experience short-term side effects.
The most common side effects after the Essure procedure include pain, cramping and vaginal bleeding. Headaches, nausea, dizziness and vomiting may also occur. Some women experience pelvic or back discomfort.
These Essure side effects usually only last a few days, according to Bayer. Bayer recommends that women have someone drive them home after the procedure.
It takes about three months for Essure to work. Women must get the Essure Confirmation Test to make sure they cannot get pregnant.
The confirmation test uses a transvaginal ultrasound (TVU) or a vaginal X-ray exam called a modified HSG.
Women who had chemotherapy or corticosteroid treatment should not undergo TVU. The HSG may expose women to low levels of radiation.
From November 2002 to December 2017, the FDA received 26,773 Essure side effect reports. The FDA calls these reports adverse events.
Each report contained multiple side effect complaints. Pain or pelvic pain was the most commonly reported Essure side effect.
Some experts challenge the FDA’s Essure data. For example, former FDA analyst Madris Tomes uncovered data the FDA had not reported.
FDA reporting is voluntary. So, there could be more unreported side effects of Essure.
In 2016, the FDA required a black box warning for Essure. This is the agency’s strongest warning.
The black box warning includes serious side effects such as organ perforation, allergic reactions and device migration. It says additional surgery may be required to treat these Essure complications.
In 2018, the FDA restricted Essure sales. Bayer only sells Essure in the U.S.
Only health care facilities and providers who use an FDA-approved checklist can buy and implant Essure. The checklist is the Patient-Doctor Discussion Checklist – Acceptance of Risk and Informed Decision Acknowledgement. It is a part of the patient information booklet.
“The sale and distribution of this device are restricted to users and/or user facilities that provide information to patients about the risks and benefits of this device in the form and manner specified in the approved labeling provided by Bayer.”
The FDA began a post-market safety investigation in 2016. It required Bayer to conduct more Essure side effect and effectiveness studies. Bayer is supposed to complete the study in 2023.
The study will enroll about 2,800 women. It will gather data on pregnancy, abdominal pain, uterine bleeding, allergic reactions and autoimmune disorders.
The study will also compare Essure to tubal ligation.
In October 2017, three congresswomen wrote to FDA Commissioner Scott Gottlieb. They said Bayer was moving too slowly in the study.
“The FDA cannot continue to allow Bayer to drag its feet on this post-market study while women are continuing to suffer.”
Please seek the advice of a medical professional before making health care decisions.
Calling this number connects you with Wilson and Peterson, LLP or one of its trusted legal partners. A law firm representative will review your case for free.
Wilson and Peterson, LLP funds Drugwatch because it supports the organization’s mission to keep people safe from dangerous drugs and medical devices.(855) 705-7637